Background: Gastric cancer is still one of the most common malignant tumors worldwide. Survivin; a novel member of the inhibitor of apoptosis protein (IAP) family is a unique inhibitor of apoptosis that has been found in various human cancers. Its expression is associated with tumor progression and adverse outcome. Aim of the work: The current study was conducted to evaluate the expression pattern of Survivin in gastric carcinoma by immunohistochemistry and to correlate the relationship between its expression with various clinicopathological parameters and the patients’ survival. Patients and methods: 30 patients with gastric carcinoma were included in this study. The expression pattern of Survivin protein was evaluated by immunohistochemistry in formalin-fixed paraffin-embedded blocks from 30 surgically resected gastric cancer tissues cases. Results: The positive expression of Survivin in gastric cancer tissues was demonstrated in 66.7% (20 out of 30) of cases. Positive staining pattern of Survivin protein was associated significantly with tumors larger than 5cm and undifferentiated carcinomas (P<0.05). Survivin expression was more frequent in diffuse tumors (72.7%) than in intestinal (66.7%) and mixed type (60%) carcinomas. There was no significant association between Survivin expression and the invasion depth of the tumor, lymph node involvement and tumor stage (P>0.05). The overall survival was 60% for Survivin positive patients as compared to 80% for Survivin negative patients (P>0.05). Conclusion: Our results suggest that Survivin may be a useful biomarker of prognosis in patients with gastric cancer and consequently increased expression of Survivin would be expected to predict a poor prognosis. Survivin may aid in a more accurate prediction of the clinical outcome of gastric cancer and may also be a novel therapeutic target. Key words: Survivin –Immunohistochemistry – Gastric cancer.